Skip to content
Assyro AI
FDA Orange Book ยท active-ingredient family

Hydralazine hydrochloride; hydrochlorothiazide; reserpine

Hydralazine hydrochloride; hydrochlorothiazide; reserpine: 1 brand, 15 generics; first approved May 13, 1982; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 15 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
15
Listed patents
0
Presentations
16

Brand (NDA) products

Originator applications
Ask AI
  • NDA 012193-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-

Generic (ANDA) products (15)

Abbreviated applications
Ask AI
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 084897-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
    ANDA 087085-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 084876-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 083877-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 087210-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 085893-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-
  • ANDA 086298-
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    25MG;15MG;0.1MGTABLETORALDiscontinued-

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
Ask AI
First approval
45 yr 1 mo ago
Most recent approval
43 yr 2 mo ago

Approvals span 1982โ€“1984 across 16 FDA applications.

Brand (NDA) 16%
Generic (ANDA) 1594%

Hydralazine hydrochloride; hydrochlorothiazide; reserpine: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Hydralazine hydrochloride; hydrochlorothiazide; reserpine

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo